ECP
CLPT icon

Epacria Capital Partners’s ClearPoint Neuro CLPT Stock Holding History

Epacria Capital Partners’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107K Hold
11,729
– – 0.08% 29
2025
Q4 		$160K Hold
11,729
– – 0.13% 31
2025
Q3 		$256K Hold
11,729
– – 0.21% 31
2025
Q2 		$140K Buy
+11,729
New +$148K 0.12% 33

Other funds holding CLPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Epacria Capital Partners's CLPT Position: Q1 2026 in Review

Epacria Capital Partners held its ClearPoint Neuro (CLPT) position steady in Q1 2026 at 11,729 shares worth $107K. The position accounts for 0.08% of the portfolio, ranked #29.

Epacria Capital Partners first reported a position in CLPT in Q2 2025 and has held it in 4 quarters since. The position peaked at $256K in Q3 2025. 118 funds tracked by Wall St. Rank hold CLPT as of Q1 2026.

  • Epacria Capital Partners held 11,729 shares of ClearPoint Neuro worth $107K as of Q1 2026.
  • Epacria Capital Partners left its ClearPoint Neuro share count unchanged in Q1 2026.
  • ClearPoint Neuro made up 0.08% of Epacria Capital Partners's portfolio in Q1 2026, its #29 holding.
  • Epacria Capital Partners first reported a position in ClearPoint Neuro in Q2 2025 and has held it in 4 quarters since.
  • Epacria Capital Partners's ClearPoint Neuro position peaked at $256K in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2026.

Based on Epacria Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.